Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study. Issue 4 (30th May 2022)

• Record Type: Journal Article
• Authors: Durmo, Rexhep; Donati, Benedetta; Rebaud, Louis; Cottereau, Anne Segolene; Ruffini, Alessia; Nizzoli, Maria Elena; Ciavarella, Sabino; Vegliante, Maria Carmela; Nioche, Christophe; Meignan, Michel; Merli, Francesco; Versari, Annibale; Ciarrocchi, Alessia; Buvat, Irene; Luminari, Stefano
• Is Part Of: Hematological oncology. Volume 40:Issue 4(2022)
• Page Start: 645
• Page End: 657
• Publication Date: 2022-05-30
• Subjects: Dmax -- gene expression profiling -- Hodgkin's lymphoma -- PET -- tumor dissemination -- tumor microenvironment; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.3025
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: We evaluated the prognostic role of the largest distance between two lesions (Dmax), defined by positron emission tomography (PET) in a retrospective cohort of newly diagnosed classical Hodgkin Lymphoma (cHL) patients. We also explored the molecular bases underlying Dmax through a gene expression analysis of diagnostic biopsies. We included patients diagnosed with cHL from 2007 to 2020, initially treated with ABVD, with available baseline PET for review, and with at least two FDG avid lesions. Patients with available RNA from diagnostic biopsy were eligible for gene expression analysis. Dmax was deduced from the three‐dimensional coordinates of the baseline metabolic tumor volume (MTV) and its effect on progression free survival (PFS) was evaluated. Gene expression profiles were correlated with Dmax and analyzed using CIBERSORTx algorithm to perform deconvolution. The study was conducted on 155 eligible cHL patients. Using its median value of 20 cm, Dmax was the only variable independently associated with PFS (HR = 2.70, 95% CI 1.1–6.63, pValue = 0.03) in multivariate analysis of PFS for all patients and for those with early complete metabolic response (iPET‐). Among patients with iPET‐low Dmax was associated with a 4‐year PFS of 90% (95% CI 82.0–98.9) significantly better compared to high Dmax (4‐year PFS 72.4%, 95% CI 61.9–84.6). From the analysis of gene expression profiles differences in Dmax were mostly associated with variations in the expression of microenvironmental components. In conclusion our results support tumor dissemination measured through Dmax as novel prognostic factor for cHL patients treated with ABVD.